HongKong:2616

CStone appoints seasoned pharmaceutical executive Shirley Zhao as the General Manager for Greater China and Head of Commercial

SUZHOU, China, Dec. 6, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced the appointment of Ms.Shirley Zhao to the position of General Manager forGreater China and Head of Commercial. In this position, Ms. Zhao will be responsible for the commerci...

2019-12-06 18:53 643

CStone announces first patient dosed in the Phase I bridging registrational study of ivosidenib

SUZHOU, China, Nov. 20, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced that the first patient has been dosed in the Phase I bridging registrational study of ivosidenib (TIBSOVO®) in China. This stand-alone trial is designed to validate the effi...

2019-11-20 11:41 519

ASH 2019 | CStone's anti-PD-L1 antibody demonstrates a complete response rate of 31.8% in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma

SUZHOU, China, Nov. 7, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced that an abstract on the CS1001-201 trial (Abstract #2833) was accepted by the 2019 American Society of Hematology (ASH) Annual Meeting and has been published online yesterday...

2019-11-07 11:02 484

ESMO 2019: CStone presents pooled safety data from the Phase 1b trial of CS1001, demonstrating promising overall safety and tolerability

SUZHOU, China, Sept. 30, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) released pooled safety data from the Phase Ib (GEMSTONE-101) study of the Company's anti-PD-L1 antibody CS1001 in a poster presentation at the European Society of Medical Oncology 2019 Con...

2019-09-30 18:29 541

2019 CSCO| CStone announces promising ORR, anti-tumor activity and safety data with its anti-PD-L1 antibody CS1001 in MSI-H/dMMR solid tumors

SUZHOU, China, Sept. 22, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced results from the microsatellite instability high/deficient mismatch repair (MSI-H/dMMR) solid tumor cohort in the GEMSTONE-101 Phase Ib study of the Company's investigation...

2019-09-22 14:22 870

2019 CSCO | CStone announces preliminary results from Phase I trial of CS1002 demonstrating characteristics comparable to ipilimumab

SUZHOU, China, Sept. 22, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced preliminary results from the Phase Ia trial of the Company's anti-CTLA-4 antibody in an oral presentation at the 22nd Annual Meeting of the Chinese Society of Clinical Onco...

2019-09-22 13:39 1016

2019 CSCO | CStone releases preliminary results from the Phase Ia trial of CS1003 in Chinese patients with advanced tumors

SUZHOU, China, Sept. 21, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today released the preliminary data from the Phase I bridging study of the Company's investigational anti-PD-1 monoclonal antibody CS1003 for the first time, in an oral presentation at the...

2019-09-21 00:26 1106

2019 CSCO | CStone announces promising trial data on its anti-PD-L1 antibody in esophageal squamous cell carcinoma with an ORR of 77.8%

SUZHOU, China, Sept. 19, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced trial data from the esophageal squamous cell carcinoma (ESCC) cohort of a Phase Ib clinical trial of the Company's investigational anti-PD-L1 antibody CS1001 in an oral pre...

2019-09-19 23:48 1366

CStone announces first patient dosed in China for Phase I/II registrational bridging trial of avapritinib in advanced GIST

SUZHOU, China, Aug. 26, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616) today announced that the first patient inChina has been dosed in the Phase I/II bridging study of avapritinib, which was discovered by CStone's partner Blueprint Medicines. This stand-alone registrational b...

2019-08-26 11:21 1513

CStone announces data from trials of CS1001, CS1002 and CS1003 to be released for the first time at 2019 CSCO Annual Meeting

SUZHOU, China, Aug. 23, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced that the 22nd Annual Meeting of the Chinese Society of Clinical Oncology (CSCO, 2019 CSCO Annual Meeting) has accepted three abstracts on the clinical trials of CS1001 (Anti...

2019-08-23 11:26 1794

CStone completes registration filing for the Phase I trial of CDK4/6 inhibitor CS3002 in Australia and will soon initiate the study

SUZHOU, China, Aug. 23, 2019 /PRNewswire/ --  CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced that the Company has recently received ethics approval from the Human Research Ethics Committee inAustralia for the Phase I clinical trial of CS3002, andAustralia's Therape...

2019-08-23 11:20 1240

CStone submits an abstract on CS1001-201 trial to 2019 ASH Annual Meeting

SUZHOU, China, Aug. 20, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616) today announced that an abstract on the company's CS1001-201 trial has been submitted to the upcoming 2019 American Society of Hematology (ASH) Annual Meeting. This will mark the first release of CS1001-201...

2019-08-20 10:18 3729

Abstract on CStone's CS1001-101 trial accepted for poster presentation at ESMO 2019 Annual Congress

SUZHOU, China, Aug. 19, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616) today announced that an abstract on the company's ongoing CS1001-101 Phase Ib clinical study has been accepted for poster presentation at the upcoming European Society for Medical Oncology (ESMO) 2019 Annua...

2019-08-19 13:50 4122

CStone Pharmaceuticals Reports First Half 2019 Financial Results

SHANGHAI, Aug. 15, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX: 2616), a leading biopharmaceutical company focused on developing and commercializing innovative immuno-oncology therapies and molecularly-targeted drugs for the treatment of cancer, today released its recent business ...

2019-08-15 15:31 5207

CStone announces first patient dosed in China with BLU-667 for the global Phase I registrational study

SUZHOU, China, Aug. 13, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616) today announces the dosing of the first patient inChina for the Phase I registrational study of BLU-667, which was discovered by the company's partner Blueprint Medicines. This clinical trial is a part of t...

2019-08-13 12:21 6272

CStone to Build Global R&D Headquarters and Industrialization Base in the Suzhou Industrial Park

SUZHOU, China, Aug. 7, 2019 /PRNewswire/ -- The signing ceremony for CStone Pharmaceuticals' ("CStone") (HKEX: 2616) Global R&D Headquarters and Industrialization Base ("the Project") took place in Suzhouon August 6. The event marks the building of yet another state-of-the-art research and devel...

2019-08-07 14:47 6992

CStone receives approval in China to initiate ivosidenib Phase I bridging registrational study for the treatment of IDH1 mutant relapsed or refractory AML

SUZHOU, China, July 22, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX: 2616) announced today that it has received approval from China National Medical Products Administration (NMPA) to initiate a Phase I bridging registrational study of ivosidenib (TIBSOVO) for the treatment of rela...

2019-07-22 12:17 6505

CStone announces first patient dosed in China with avapritinib in global Phase III clinical trial in advanced GIST

SUZHOU, China, July 9, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616) today announced that the first patient has been dosed inChina with avapritinib in the ongoing global Phase III VOYAGER clinical trial. This study is designed to evaluate the safety and efficacy of avapritini...

2019-07-10 10:23 6802

CStone and Bayer announce global collaboration to evaluate PD-L1 monoclonal antibody CS1001 in combination with regorafenib

SUZHOU, China, June 9, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX: 2616) today announced that the company has entered into a global clinical collaboration withChina focus with Bayer HealthCare LLC to evaluate the safety, tolerability, pharmacokinetics (PK) and antitumor activity ...

2019-06-10 09:30 6644

CStone received approval to initiate clinical development in China of CS1001 and BLU-554 (CS3008) in combination therapy for HCC

SUZHOU, China, June 5, 2019 /PRNewswire/ -- CStone Pharmaceuticals (CStone; HKEX: 2616) announced that it has received approval to initiate clinical development inChina of CS1001 in combination with BLU-554 (CS3008) in patients with locally advanced or metastatic hepatocellular carcinoma (HCC). T...

2019-06-05 19:56 6513
12